Zobrazeno 1 - 10
of 240
pro vyhledávání: ''
Autor:
Nassim Djebli, Pierre-Olivier Tremblay, Vincent Buchheit, Mario González-Sales, Guillaume Bonnefois, Georgina Meneses-Lorente, Francois Mercier, Nicolas Frey
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:997-1007
Entrectinib (ROZLYTREK®) is a CNS-active, potent, and selective inhibitor of ROS1, TRK A/B/C, and ALK kinase activity. It was recently approved for the treatment of ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors.
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:533-542
Genetic variation in the activation of the prodrug cyclophosphamide (CP) by cytochrome P450 (CYP) enzymes has been shown to influence outcomes. However, CYP are also subject to phenoconversion due to either the effects of comedications or cancer asso
Autor:
Chien-Liang Liu, Yuan-Ching Chang, Chun-Yi Wu, Ming-Jen Chen, Wen-Chien Huang, Shih-Ping Cheng, Chi-Hsin Lin, Jiunn-Chang Lin
Publikováno v:
Investigational New Drugs. 39:1493-1506
Background Human 3β-hydroxysteroid dehydrogenase type 1 (HSD3B1) is an enzyme associated with steroidogenesis, however its' role in hepatocellular carcinoma (HCC) biology is unknown. Trilostane is an inhibitor of HSD3B1 and has been tested as a trea
Autor:
Benjamin Wu, Mathilde Marchand, Nitzan Sternheim, Rene Bruno, Valerie Quarmby, Marcus Ballinger, Rong Zhang, Jin Y. Jin, Phyllis Chan
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:211-221
The time-varying clearance (CL) of the PD-L1 inhibitor atezolizumab was assessed on a population of 1519 cancer patients (primarily with non-small-cell lung cancer or metastatic urothelial carcinoma) from three clinical studies. The first step was to
Autor:
Hélène Behal, Anthony Turpin, Simon Baldacci, Enora Vauléon, Renaud Desbarbieux, Nicolas Simon, Marie-Hélène Vieillard, Diane Pannier, Loïc Lebellec
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:533-541
The occurrence of arthralgia and myalgia during treatment with bevacizumab (Bev) has been described but not spontaneously reported. We aimed to evaluate the frequency of arthralgia in patients treated with Bev and identify the risk factors. In this o
Autor:
Takahisa Suzuki, Sohgo Tsutsumi, Hisashi Hasumi, Go Noguchi, Kimito Osaka, Kentaro Muraoka, Yuka Igarashi, Keiichi Kondo, Yosuke Shibata, Shinji Ohtake, Tetsuro Sasada, Masato Yasui, Susumu Umemoto, Noboru Nakaigawa, Kota Kobayashi, Takeshi Kishida, Masahiro Yao
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:75-85
Nivolumab is part of the standard therapy for mRCC. Although deep and long-lasting responses are seen in some patients, the benefit of treatment is limited to some patients and the majority of patients will experience disease progression. PD-L1 is st
Autor:
M. Teresa Agulló-Ortuño, Luis Paz-Ares, Lara Iglesias, Virginia Pardo-Marqués, Juan A. Núñez, Jon Zugazagoitia, Inmaculada García-Ruiz, C. Vanesa Díaz-García, Jose A. Lopez-Martin, Elena Prieto-García, Ana Belén Enguita, Santiago Ponce
Publikováno v:
Cancer Chemotherapy and Pharmacology. 85:525-535
Therapeutic options for cancer patients have increased in the last years, although drugs resistance problem remains unresolved. Genetic background in individual susceptibility to cancer treatment could influence the therapy responses. The aim of this
Autor:
Yutaka Fujiwara, Toshio Shimizu, Shunsuke Kondo, Takafumi Koyama, Akihiko Shimomura, Noboru Yamamoto, Shigehisa Kitano, Satoru Iwasa, Takahiro Ebata, Kan Yonemori
Publikováno v:
Cancer Chemotherapy and Pharmacology. 85:449-459
This study aimed to compare the survival of patients enrolled in phase 1 trials in recent decades. The medical records of consecutive patients with advanced cancer who participated in single-agent oncology phase 1 trials from 1995 to 2015 at a single
Autor:
Jennifer Caplain, Madhumita Das, Elizabeth Grimm, Shrikar Rajagopal, Oksana B. Serebrennikova, Robert E. Martell, Philip N. Tsichlis, Mohammad Wasif Saif
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:1323-1331
Metformin activates AMP-related pathways leading to inactivation of mammalian target of rapamycin (mTOR) and suppression of its downstream effectors, crucial for cancer growth. Epidemiologic studies showed a reduced incidence and improved survival in
Autor:
Heinz Joseph Lenz, Thehang Luu, Edward M. Newman, Mihaela C. Cristea, Dean Lim, Paul Frankel, Leonard Joseph Appleman, David R. Gandara, Richard Piekarz, Brian F. Kiesel, Jan H. Beumer
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: The reported maximum tolerated dose (MTD) of single agent belinostat is 1000 mg/m(2) given days 1-5, every 21 days. Pre-clinical evidence suggests histone deacetylase inhibitors enhance retinoic acid signaling in a variety of solid tumors. W